PCa Commentary #149 – LUPRON vs FIRMAGON: Is The Debate About Superiority Over? Just the Facts, Please, … but with the December FDA approval of Relugolix the debate may now be moot.

A great deal has been written about the comparison between Lupron (leuprolide) and Firmagon (degarelix). Lupron as been the mainstay of treatment of relapsed and metastatic prostate cancer since its introduction in the early 1990’s.  Firmagon (degarelix) was FDA...